Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 19/20 | 0.60 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL657656 | 1.00 | PPARD (0.60) | PPARDPTGDR2PPARA | |
| SCHEMBL5959361 | 0.96 | PPARD (0.65) | PPARDPPARA | |
| SCHEMBL657260 | 0.92 | PPARD (0.61) | PPARDPPARA | |
| SCHEMBL657259 | 0.92 | PPARD (0.61) | PPARDPPARA | |
| SCHEMBL657484 | 0.92 | PPARD (0.65) | PPARDPPARA | |
| SCHEMBL657485 | 0.92 | PPARD (0.65) | PPARDPPARA | |
| SCHEMBL655751 | 0.92 | PPARD (0.73) | PPARDPPARA | |
| SCHEMBL655750 | 0.92 | PPARD (0.73) | PPARDPPARA | |
| SCHEMBL657036 | 0.90 | PPARD (0.66) | PPARDPTGDR2PPARA | |
| SCHEMBL657037 | 0.90 | PPARD (0.66) | PPARDPTGDR2PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558571-B1 | NOVEL COMPOUNDS USEFUL IN TREATING PPAR MEDIATED DISEASES | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-06-02 | — | — | EP | claimed |
| US-7709528-B2 | Compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-05-04 | — | — | US | claimed |
| US-20060287393-A1 | Novel compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2006-12-21 | — | — | US | claimed |
| EP-1558571-A1 | NOVEL COMPOUNDS USEFUL IN TREATING PPAR MEDIATED DISEASES | NOVO NORDISK A/S (DK) | 2005-08-03 | — | — | EP | claimed |
| US-20050080115-A1 | Novel compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2005-04-14 | — | — | US | claimed |
| WO-2004037775-A1 | NOVEL COMPOUNDS USEFUL IN TREATING PPAR MEDIATED DISEASES | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | WO | claimed |
| US-20120046350-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-02-23 | — | — | US | disclosed |
| EP-1558571-B1 | NOVEL COMPOUNDS USEFUL IN TREATING PPAR MEDIATED DISEASES | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-06-02 | — | — | EP | disclosed |
| US-7709528-B2 | Compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-05-04 | — | — | US | disclosed |
| US-20060287393-A1 | Novel compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2006-12-21 | — | — | US | disclosed |
| US-20050080115-A1 | Novel compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287393-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | PPARD 2/4885PTGDR2 65/4885PPARA 3/4885 |
| US-20050080115-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | PPARD 2/4885PTGDR2 65/4885PPARA 3/4885 |
| US-20120046350-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | PPARG, PPARD, PPARA | PPARD 2/4885PTGDR2 65/4885PPARA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.